Advanced in Urothelial Cancer

Dr. Chong-xian X. Pan

Hematology Oncology | Oncology
2279 45th Street, 
Sacramento, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Urothelial Cancer
2279 45th Street, 
Sacramento, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Chong-xian Pan is a Hematologist Oncology specialist and an Oncologist in Sacramento, California. Dr. Pan is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Bladder Cancer, Prostate Cancer, Familial Prostate Cancer, and Urothelial Cancer.

His clinical research consists of co-authoring 89 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 2 clinical trials in the study of Urothelial Cancer.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

2279 45th Street, Sacramento, CA 95817
Other Locations
1400 Vfw Pkwy, West Roxbury, MA 02132

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Enrollment Status: Recruiting
Publish Date: December 11, 2025
Intervention Type: Procedure, Drug, Biological, Other
Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim
Study Phase: Phase 2
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Eribulin Mesylate
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 1
Phase Ib/II Trial of Ibrutinib Plus Nivolumab in Patients With Previously-Treated Metastatic Renal Cell Cancer
Phase Ib/II Trial of Ibrutinib Plus Nivolumab in Patients With Previously-Treated Metastatic Renal Cell Cancer
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Pilot Study Using Parametric PET to Assess Early Treatment Response to Targeted Therapy for Genitourinary Cancer (GUC)
Pilot Study Using Parametric PET to Assess Early Treatment Response to Targeted Therapy for Genitourinary Cancer (GUC)
Enrollment Status: Completed
Publish Date: January 20, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Niclosamide, Prednisone
Study Phase: Phase 2
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Safety Trial of Enzalutamide in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
A Safety Trial of Enzalutamide in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
Enrollment Status: Completed
Publish Date: April 26, 2023
Intervention Type: Drug
Study Drugs: Enzalutamide, Niclosamide
Study Phase: Phase 1
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 26, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

89 Total Publications

Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance.
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance.
Journal: JAMA oncology
Published: November 20, 2025
Similar Doctors
Distinguished in Urothelial Cancer
Dr. Mamta Parikh
Hematology Oncology | Hematology | Oncology
Distinguished in Urothelial Cancer
Dr. Mamta Parikh
Hematology Oncology | Hematology | Oncology

Regents Of The Univ Of Ca

2315 Stockton Blvd, 
Sacramento, CA 
 (0.2 miles away)
916-734-2011
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mamta Parikh is a Hematologist Oncology specialist and a Hematologist in Sacramento, California. Dr. Parikh is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. Her top areas of expertise are Prostate Cancer, Urothelial Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, and Bone Marrow Aspiration.

Distinguished in Urothelial Cancer
Dr. Primo N. Lara
Hematology Oncology | Hematology | Oncology
Distinguished in Urothelial Cancer
Dr. Primo N. Lara
Hematology Oncology | Hematology | Oncology

Regents Of The Univ Of Ca

4501 X St, 
Sacramento, CA 
 (0.1 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Primo Lara is a Hematologist Oncology specialist and a Hematologist in Sacramento, California. Dr. Lara is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

Advanced in Urothelial Cancer
Dr. David L. Campbell
Hematology Oncology | Hematology | Oncology
Advanced in Urothelial Cancer
Dr. David L. Campbell
Hematology Oncology | Hematology | Oncology

Dignity Health Medical Foundation

155 Glasson Way, Suite L 10, 
Grass Valley, CA 
 (51.4 miles away)
530-274-6677
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Campbell is a Hematologist Oncology specialist and a Hematologist in Grass Valley, California. Dr. Campbell is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Gastric Lymphoma, Paget Disease of the Breast, Non-Hodgkin Lymphoma, and Inflammatory Breast Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pan's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile